KOD · Kodiak Sciences Inc.
$32.89
+0.02 (+0.06%)
At close · Sep 11
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, we had cash and cash equivalents of $125.9 million. We have incurred net losses and negative cash flows from operations since inception. We expect to continue to incur operating losses and negative operating cash flows for the foreseeable future and as a result, there is substantial doubt regarding our ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$2.07B
Shares
62.85M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$32.89
Open$33.10
Day$32.31–34.07
52W close$9.21–46.44
Avg vol 30d587K
Short int10.8M · 17.2% float · 18.5d
Short vol62%
Last earningsNov 13, 2025
DataJan 2020–Sep 2026
Filing10-Q · Aug 13
Up next
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$241.99M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-7.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+18.7%
Year over year · more shares
Price change (1Y)
+231.6%
Trailing year
Short interest
17.2%
Latest settlement · 18.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Strong
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−2%
below
Price vs 50-day avg
−18%
below
RSI (14)
29
oversold
MACD trend
Negative
52-week position
64%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−18%
trailing
6-month return
+48%
trailing
YTD return
+18%
this year
Relative strength
+30%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $40 › 200d $33 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +38 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
17.15% of float · ▲ +4.6% MoM · 18.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
203 holders — near 3-yr high, broad support
Squeeze score
66
elevated · 0–100
Fundamentals
EPS growth
−29%
Y/Y
Free cash flow
$-136.5M
Quant / Vol
risk profile
Volatility
126%
annualized · 1-yr
Max drawdown
−36%
past year
ATR
6.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−2%
Neutral
Price vs 50-day avg
−18%
Bearish
RSI (14)
29
Neutral
MACD trend
Negative
Bearish
52-week position
64%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $40 › 200d $33 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +38 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
17.15% of float · ▲ +4.6% MoM · 18.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
203 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $9
Now $33 · 64%
Range high $46
vs 200-day avg -2%
vs 50-day avg -18%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KOD
this stock
Kodiak Sciences Inc.
|
$2.07B | +17.6% | — | — | 17.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.22B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KOD | -9.5% | -17.7% | +47.8% | -11.9% | +17.6% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -8.4% | -16.0% | +30.0% | -11.6% | +5.6% |